Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB2 | P47870 | 5/20 | 0.67 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.67 |
| ▸ | ALB | P02768 | 2/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933323 | 0.95 | GABRB2 (0.64) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL6011803 | 0.85 | GABRA1 (0.73) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL1761287 | 0.83 | GABRA1 (0.74) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL2929266 | 0.83 | GABRA1 (0.74) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL14088713 | 0.82 | GABRA1 (0.57) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL14797241 | 0.82 | GABRA1 (0.73) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL2929147 | 0.82 | GABRB2 (0.73) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL4255837 | 0.81 | GABRA1 (0.61) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL2935064 | 0.81 | GABRB2 (0.71) | GABRB2GABRA1ALBOPRK1KCNH2 | |
| SCHEMBL4265939 | 0.81 | GABRA1 (0.57) | GABRB2GABRA1ALBOPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682549-B1 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR INC (US) | 2010-09-22 | — | — | EP | disclosed |
| EP-1682549-B1 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR INC (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723324-B2 | Imidazo[1,2-A]pyridine anxiolytics | SEPRACOR, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566725-B2 | Imidazo[1,2-A] pyridine anxiolytics | SEPRACOR INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | SEPRACOR INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | SEPRACOR INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-7148353-B2 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | SEPRACOR INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005044818-A2 | IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS | SEPRACOR, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043074-A1 | IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS | CNR1, CNR2, GABRA5 | GABRB2 25/4885GABRA1 4/4885ALB 3804/4885 |
| US-20050171144-A1 | Imidazo[1,2-a] pyridine anxiolytics | CNR1, CNR2, GABRA5 | GABRB2 25/4885GABRA1 4/4885ALB 3804/4885 |
| US-20080096867-A1 | Imidazo[1,2-A] Pyridine Anxiolytics | MTNR1B, ADORA2B, ADRA2B | GABRB2 13/4885GABRA1 37/4885ALB 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.